NPJ Breast Cancer最新文献_第7页

Proteomic landscape of decellularized breast carcinomas identifies C-type lectin domain family 3 member A as a driver of cancer aggressiveness. 脱细胞乳腺癌的蛋白质组学研究发现c型凝集素结构域家族3成员A是癌症侵袭性的驱动因素。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-06-06 DOI: 10.1038/s41523-025-00769-0

Tiziana Triulzi, Marta Giussani, Elisa Maffioli, Viola Regondi, Ewelina J Lorenc, Valeria Arlotta, Francesca Bianchi, Sabina Pozzi, Martina Varricchio, Valeria Cancila, Cesare Valenti, Marco Sandri, Alessandro Podestà, Lucia Sfondrini, Giovanni Vozzi, Gabriella Tedeschi, Serenella M Pupa, Elda Tagliabue

{"title":"Proteomic landscape of decellularized breast carcinomas identifies C-type lectin domain family 3 member A as a driver of cancer aggressiveness.","authors":"Tiziana Triulzi, Marta Giussani, Elisa Maffioli, Viola Regondi, Ewelina J Lorenc, Valeria Arlotta, Francesca Bianchi, Sabina Pozzi, Martina Varricchio, Valeria Cancila, Cesare Valenti, Marco Sandri, Alessandro Podestà, Lucia Sfondrini, Giovanni Vozzi, Gabriella Tedeschi, Serenella M Pupa, Elda Tagliabue","doi":"10.1038/s41523-025-00769-0","DOIUrl":"10.1038/s41523-025-00769-0","url":null,"abstract":"An extracellular matrix (ECM) gene expression pattern (ECM3) distinguished truly aggressive grade III breast carcinomas (BCs). Here, we examined the biomechanical characteristics of the ECM in human BCs to identify the molecules that mediate the aggressiveness of ECM3/grade III (E3G3) tumors. By shotgun proteomics of decellularized human BCs, we found a significant enrichment in proteins involved in tumor-ECM interaction in E3G3 tumors. These tumors were characterized by high dense collagen deposition, a fibrillary cytoskeleton network and the highest stiffness. CLEC3A, a secreted C-type lectin domain family 3 member, was found unique of E3G3 tumors and was validated to be more expressed in these tumors by immunohistochemistry in 2 human BC cohorts, associating significantly with worse prognosis. Ectopic CLEC3A overexpression in MDA-MB-231, MDA-MB-361, and MDA-MB-468 BC cells increased intracellular mediators of tumor adhesion to the ECM, actin-stress fibers and YAP activation, and tumor migration. Accordingly, levels of the YAP/TAZ gene signature were higher in CLEC3A-positive ECM3-enriched tumors and correlated with tumor stiffness. These results implicate CLEC3A in mediating the ability of E3G3 BCs to sense cues in the surrounding ECM, accelerating tumor progression.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"51"},"PeriodicalIF":6.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and characterisation of a novel 3D in vitro model of obesity-associated breast cancer as a tool for drug testing. 一种新型3D肥胖相关乳腺癌体外模型的开发和表征，作为药物测试的工具。

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-05-30 DOI: 10.1038/s41523-025-00766-3

Rhianna R R Blyth, Stèphanie A Laversin, Russell B Foxall, Constantinos Savva, Ellen Copson, Ramsey I Cutress, Charles N Birts, Stephen A Beers

{"title":"Development and characterisation of a novel 3D in vitro model of obesity-associated breast cancer as a tool for drug testing.","authors":"Rhianna R R Blyth, Stèphanie A Laversin, Russell B Foxall, Constantinos Savva, Ellen Copson, Ramsey I Cutress, Charles N Birts, Stephen A Beers","doi":"10.1038/s41523-025-00766-3","DOIUrl":"10.1038/s41523-025-00766-3","url":null,"abstract":"Obesity is associated with worse breast cancer outcomes and decreased therapeutic efficacy. However, the mechanisms driving obesity-associated therapy resistance remain unclear; in part due to a lack of suitable models that recapitulate the obese tumour microenvironment. To address this, we developed a 3D in vitro model of obesity-associated breast cancer, to investigate biological mechanisms and to use as a drug testing tool. A penta-culture system was developed by co-culturing adipocyte spheroids with breast tumour cells, myoepithelial cells, macrophages, and fibroblasts in a collagen matrix. Tumour cells and macrophages infiltrated adipocyte spheroids, replicating the inflamed-adipose border typical of obese patients. This model was then assessed as a drug testing platform. Obese cultures exhibited increased sensitivity to metformin and, conversely, resistance to paclitaxel, compared to non-obese cultures. This 3D organotypic model effectively recapitulates key features of the obese adipose tumour microenvironment, providing a useful tool to interrogate mechanisms underpinning obesity-related therapy resistance.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"50"},"PeriodicalIF":7.6,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study. 炎性乳腺癌的临床病理和分子特征，前瞻性炎症登记研究。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-05-29 DOI: 10.1038/s41523-025-00764-5

Jasper J L van Geel, Elisabeth M Jongbloed, Jasmine Moustaquim, Gonneke van der Schoor, A Elise van Leeuwen-Stok, Marcel Smid, Carolien H M van Deurzen, Saskia M Wilting, Jelle Wesseling, Gabe S Sonke, John W M Martens, Carolina P Schröder

{"title":"Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study.","authors":"Jasper J L van Geel, Elisabeth M Jongbloed, Jasmine Moustaquim, Gonneke van der Schoor, A Elise van Leeuwen-Stok, Marcel Smid, Carolien H M van Deurzen, Saskia M Wilting, Jelle Wesseling, Gabe S Sonke, John W M Martens, Carolina P Schröder","doi":"10.1038/s41523-025-00764-5","DOIUrl":"10.1038/s41523-025-00764-5","url":null,"abstract":"Inflammatory breast cancer (IBC) is rare, with challenging diagnostics and unfavorable outcomes. Therefore, more molecular insight into IBC is needed. The comprehensive Dutch prospective INFLAME registry related IBC follow-up and treatment to histopathology and molecular analysis. Of consecutive patients, nationwide identified with newly diagnosed IBC, clinicopathological, treatment and outcome data were collected. Histopathology and RNA-sequencing were related to outcome. 125 IBC patients were enrolled. Forty-one (34%) patients had HER2 + , and 31 (25%) had triple-negative IBC. The estimated 3-year OS was 78% in M0 IBC and 29% in M1. PFS was worst in triple-negative IBC (median 7.9 vs 16.3 and 15.8 months in M1 HER2+ and HR + /HER2- IBC). DFS and OS in M0 IBC were better with guideline-concordant trimodal therapy than without (HR 0.15 and 0.15; p = 0.000005 and 0.00038). The unique prospective INFLAME confirms unfavorable IBC characteristics and outcomes. International efforts may support guideline adherence and identify IBC-specific targets.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"48"},"PeriodicalIF":6.5,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study). 一项实用的、多中心的、随机试验，比较早上和晚上给药的辅助内分泌治疗（REaCT-CHRONO研究）。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-05-29 DOI: 10.1038/s41523-025-00762-7

M F Savard, M Ibrahim, D Saunders, G R Pond, T L Ng, A A Awan, S Sehdev, N Alqahtani, L Vandermeer, F MacDonald, A A Beltran-Bless, L Fallowfield, M Clemons

{"title":"A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study).","authors":"M F Savard, M Ibrahim, D Saunders, G R Pond, T L Ng, A A Awan, S Sehdev, N Alqahtani, L Vandermeer, F MacDonald, A A Beltran-Bless, L Fallowfield, M Clemons","doi":"10.1038/s41523-025-00762-7","DOIUrl":"10.1038/s41523-025-00762-7","url":null,"abstract":"The time of day of administration (chronotherapy) of certain medications can affect both their toxicity and efficacy. In this pragmatic, multicenter trial, women starting adjuvant endocrine therapy (ET) for hormone receptor-positive early-stage breast cancer were randomized (1:1) to either morning or evening administration. The primary endpoint was endocrine toxicity/tolerability measured by the change in total Functional Assessment of Cancer Therapy-Endocrine Subscale (FACT-ES) score from baseline to 12-weeks. Secondary endpoints included: endocrine toxicity/tolerability and quality of life (FACT-ES and FACT-B) from baseline to 4, 8, 12, and 52 weeks, non-persistence or non-adherence, and patient preference for timing of ET. Between June 30, 2021, and March 18, 2022, 245 eligible participants were randomized to either morning (122/245, 49.8%) or evening ET (123/245, 50.2%). In the overall population, there was no statistical difference in the change in total FACT-ES score from baseline to 12 weeks (p = 0.086). There were no statistically significant differences for any of the secondary endpoints between the two groups. The study provides evidence for the enthusiasm of patients and investigators to take part in chronotherapy studies. Additional prospective studies should be performed to assess how the timing of ET affects survival outcomes to ensure optimal patient care. Trial Registration: ClinicalTrials.gov, NCT04864405.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"49"},"PeriodicalIF":6.5,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment patterns and clinical outcomes of patients with HER2-positive T1micN0 breast cancer: a single-center analysis. her2阳性T1micN0乳腺癌患者的治疗模式和临床结果：单中心分析

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-05-24 DOI: 10.1038/s41523-025-00759-2

Celine Yeh, Rachel Han, Abha Kulkarni, Charlie White, Yuan Chen, Matthew G Hanna, Edi Brogi, Andrew D Seidman

引用次数: 0

Predicting pathologic ≥N2 disease in women with breast cancer. 预测乳腺癌患者病理≥N2疾病。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-05-22 DOI: 10.1038/s41523-025-00757-4

Kerollos Nashat Wanis, Wenli Dong, Yu Shen, Funda Meric-Bernstam, Taiwo Adesoye, Henry M Kuerer, Abigail S Caudle, Nina Tamirisa, Sarah M DeSnyder, Susie X Sun, Isabelle Bedrosian, Puneet Singh, Solange E Cox, Kelly K Hunt, Rosa F Hwang

{"title":"Predicting pathologic ≥N2 disease in women with breast cancer.","authors":"Kerollos Nashat Wanis, Wenli Dong, Yu Shen, Funda Meric-Bernstam, Taiwo Adesoye, Henry M Kuerer, Abigail S Caudle, Nina Tamirisa, Sarah M DeSnyder, Susie X Sun, Isabelle Bedrosian, Puneet Singh, Solange E Cox, Kelly K Hunt, Rosa F Hwang","doi":"10.1038/s41523-025-00757-4","DOIUrl":"10.1038/s41523-025-00757-4","url":null,"abstract":"The distinction between pN1 and ≥pN2 breast cancer impacts treatment decisions. Using data from a single institution on women with cN0 invasive breast cancer who were treated with upfront surgery, had 1-3 positive SLNs, and underwent completion ALND, we used gradient boosted trees (XGBoost) to develop a model for predicting ≥pN2 disease using clinicopathologic variables. Model performance was tested in a held-out subsample (20%) and validated using data from the National Cancer Database (NCDB). Of 3574 patients with cN0 breast cancer, 587 underwent upfront surgery and had 1-3 positive SLNs. Of these, 415 (70.7%) underwent completion ALND, with 64 (15.4%) having ≥pN2 disease. The trained algorithm had an AUC of 0.87 (95% CI: 0.74, 0.97) in the held-out test data, and 0.78 (95% CI: 0.76, 0.79) in recent NCDB data where completion ALND was much less commonly performed. The number of positive SLNs and the total number of SLNs removed had the greatest influence on model predictions in the held-out test data. The developed model effectively estimates the probability of ≥pN2 disease in cN0 patients with positive SLNs, providing guidance for the management of patients with breast cancer.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"46"},"PeriodicalIF":6.5,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of margin distance on recurrence and survival following breast-conserving surgery after neoadjuvant systemic therapy. 切缘距离对保乳术后新辅助全身治疗后复发及生存的影响。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-05-19 DOI: 10.1038/s41523-025-00756-5

C Florin Pop, Clémence Ortega, Mathilde Lecomte, Paulus Kristanto, Chirine Khaled, Filip De Neubourg, Antoine Desmet, Evandro De Azambuja, Denis Larsimont, Isabelle Veys

{"title":"Impact of margin distance on recurrence and survival following breast-conserving surgery after neoadjuvant systemic therapy.","authors":"C Florin Pop, Clémence Ortega, Mathilde Lecomte, Paulus Kristanto, Chirine Khaled, Filip De Neubourg, Antoine Desmet, Evandro De Azambuja, Denis Larsimont, Isabelle Veys","doi":"10.1038/s41523-025-00756-5","DOIUrl":"10.1038/s41523-025-00756-5","url":null,"abstract":"Current evidence does not support the application of \"no-ink-on-tumor\" negative margins following breast-conserving surgery (BCS) in breast cancer (BC) patients who have received neoadjuvant systemic treatment (NST). We compared loco-regional free survival (LRFS), disease-free survival (DFS), and overall survival (OS) based on different tumor margin distance thresholds in a cohort of 235 BC patients treated with NST and subsequent BCS between 01/2015 and 12/2019. The 5-year LRFS was 81.6% in patients with \"no-ink-on-tumour\", margins and 71.0% in those with positive margins (p = 0.584). Margins >1 mm were associated with superior outcomes, with a 5-year LRFS of 84.0% compared to 69.3% in patients with margins ≤1 mm (p = 0.005). Additionally, margins >1 mm were significantly correlated with longer DFS (p = 0.028) and OS (p = 0.001). These findings suggest that a surgical margin distance >1 mm provides the best LRFS, DFS, and OS outcomes for this group of BC patients.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"45"},"PeriodicalIF":6.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer. 揭示范式转变：小淋巴结阴性乳腺癌的系统性治疗策略。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-05-16 DOI: 10.1038/s41523-025-00761-8

Mariana Carvalho Gouveia, Mariana Scaranti, Bruna Migliavacca Zucchetti, Renata Colombo Bonadio, Romualdo Barroso-Sousa, Jose Pablo Leone

{"title":"Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer.","authors":"Mariana Carvalho Gouveia, Mariana Scaranti, Bruna Migliavacca Zucchetti, Renata Colombo Bonadio, Romualdo Barroso-Sousa, Jose Pablo Leone","doi":"10.1038/s41523-025-00761-8","DOIUrl":"10.1038/s41523-025-00761-8","url":null,"abstract":"The implementation of screening mammography has significantly altered the size distribution of breast tumors, with approximately 20% of newly diagnosed breast cancers measuring 10 mm or smaller with node-negative disease (T1aN0 and T1bN0). The management of these early-stage breast cancers remains a subject of debate. Historically, patients with T1aN0 and T1bN0 breast cancer have been excluded from adjuvant chemotherapy trials due to their excellent prognosis, with reported 10-year disease-specific survival rates exceeding 90%. However, the optimal treatment strategy for this subgroup of patients continues to be controversial, as the potential benefits of adjuvant chemotherapy must be carefully weighed against the risks of overtreatment. In this review, we summarize current evidence on outcomes and treatment strategies, highlight gaps in the literature, and provide future perspectives on the management of T1aN0 and T1bN0 breast cancer, according to immunohistochemical subtypes.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"44"},"PeriodicalIF":6.5,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification. 妊娠对乳腺癌免疫学的影响：免疫生物标志物和TIL定量。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-05-14 DOI: 10.1038/s41523-025-00758-3

Kristin Galas, Moritz Gleitsmann, Julia Rey, Christine Solbach, Isabell Witzel, Thomas Karn, Sabine Schmatloch, Christian Schem, Andreas Schneeweis, Bruno Sinn, Tanja Fehm, Carsten Denkert, Peter Fasching, Anne-Sophie Litmeyer, Frederik Marmé, Paul Jank, Volkmar Müller, Sabine Seiler, Elmar Stickeler, Olaf Ortmann, Marion van Mackelenbergh, Valentina Nekljudova, Johannes Holtschmidt, Sibylle Loibl

{"title":"Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification.","authors":"Kristin Galas, Moritz Gleitsmann, Julia Rey, Christine Solbach, Isabell Witzel, Thomas Karn, Sabine Schmatloch, Christian Schem, Andreas Schneeweis, Bruno Sinn, Tanja Fehm, Carsten Denkert, Peter Fasching, Anne-Sophie Litmeyer, Frederik Marmé, Paul Jank, Volkmar Müller, Sabine Seiler, Elmar Stickeler, Olaf Ortmann, Marion van Mackelenbergh, Valentina Nekljudova, Johannes Holtschmidt, Sibylle Loibl","doi":"10.1038/s41523-025-00758-3","DOIUrl":"https://doi.org/10.1038/s41523-025-00758-3","url":null,"abstract":"Breast cancer diagnosed during pregnancy (PrBC) is a rare occurrence but may become more prevalent as women nowadays tend to postpone childbearing until later in life. Further understanding of how pregnancy affects the tumor microenvironment (TME) is essential. We constructed Tissue Microarrays (TMA) of tumor specimens from 126 pregnant breast cancer (BC) patients and examined standard BC markers such as ER, PR, Ki67, HER2, tumor infiltrating lymphocytes (TILs), and immunomarkers HLA class I, HLA-G, PD-L1, TIGIT and Nectin-4. Subsequently, we compared our findings with those from a matched non-pregnant cohort of young BC patients. Pregnant BC patients were younger, had significantly higher proliferation rates and a higher expression of Nectin-4. Higher pregnancy related estrogen levels may boost proliferation und Nectin-4 overexpression, promoting BC progression. No further evidence supporting impaired maternal anti-tumor response in BC was observed in this study.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"43"},"PeriodicalIF":6.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel treatment approaches utilizing antibody-drug conjugates in breast cancer. 利用抗体-药物偶联物治疗乳腺癌的新方法。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-05-13 DOI: 10.1038/s41523-025-00743-w

Andrew A Davis, Jennifer Hesse, Patrícia M R Pereira, Cynthia X Ma

{"title":"Novel treatment approaches utilizing antibody-drug conjugates in breast cancer.","authors":"Andrew A Davis, Jennifer Hesse, Patrícia M R Pereira, Cynthia X Ma","doi":"10.1038/s41523-025-00743-w","DOIUrl":"10.1038/s41523-025-00743-w","url":null,"abstract":"Antibody-drug conjugates (ADCs) are rapidly changing the way we treat patients with breast cancer. Despite this progress, many unanswered questions remain regarding the sequencing of different ADCs with similar payloads, optimal combinations, drug design strategies to limit off-target toxicities, biomarkers to define antigen positivity, and the use of ADCs in the neoadjuvant and adjuvant settings. In this review, we summarize novel ADC approaches in breast cancer treatment, including potential improvements in ADC payloads, linkers, targets, and drug delivery. We also evaluate novel strategies to combine ADCs with other agents, such as targeted drugs and immune checkpoint inhibitors. To improve patient selection, the development of quantitative biomarkers is reviewed, including HER2 mRNA, immunofluorescence-based assays, mass spectrometry, liquid biopsies, digital pathology, and molecular imaging-based approaches. Lastly, we evaluate the potential to incorporate ADCs into the early-stage setting, including evaluating currently published and ongoing clinical trials. This review highlights the potential for ADCs to shift the treatment paradigm in both the advanced and early-stage settings. We further demonstrate the complexity and challenges of improving ADCs to enhance targeting of tumor vulnerabilities while limiting toxicity through rationale drug development strategies to enhance the therapeutic window, linker technology, and payload variability to continue to improve outcomes for patients with breast cancer.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"42"},"PeriodicalIF":6.5,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0